Patents Assigned to G1 Therapeutics, Inc.
  • BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS
    Publication number: 20180230123
    Abstract: This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 16, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventor: Jay Copeland Strum
  • TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY
    Publication number: 20180221378
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
  • CDK Inhibitors
    Publication number: 20180201617
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK INHIBITORS
    Publication number: 20180201618
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK INHIBITORS
    Publication number: 20180201619
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • LACTAM KINASE INHIBITORS
    Publication number: 20180127431
    Abstract: Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.
    Type: Application
    Filed: January 2, 2018
    Publication date: May 10, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventor: Francis Xavier Tavares
  • HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS
    Publication number: 20180015096
    Abstract: This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 18, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Lactam kinase inhibitors
    Patent number: 9856268
    Abstract: Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: January 2, 2018
    Assignee: G1 Therapeutics, Inc.
    Inventor: Francis Xavier Tavares
  • TRICYCLIC LACTAMS FOR USE IN HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION
    Publication number: 20170333440
    Abstract: This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 23, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Ricky D. Gaston, Robert C. Gadwood
  • Treatment Of RB-Negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors
    Publication number: 20170246171
    Abstract: This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.
    Type: Application
    Filed: March 13, 2017
    Publication date: August 31, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino
  • Lactam kinase inhibitors
    Patent number: 9745316
    Abstract: Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: August 29, 2017
    Assignee: G1 Therapeutics, Inc.
    Inventor: Francis Xavier Tavares
  • Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
    Patent number: 9717735
    Abstract: This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: August 1, 2017
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Ricky D. Gaston, Robert C. Gadwood
  • Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors
    Publication number: 20170182043
    Abstract: This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.
    Type: Application
    Filed: March 13, 2017
    Publication date: June 29, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
  • Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
    Publication number: 20170119774
    Abstract: This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.
    Type: Application
    Filed: December 7, 2016
    Publication date: May 4, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation
    Publication number: 20170100405
    Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Transient Protection of Normal Cells During Chemotherapy
    Publication number: 20170065597
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Application
    Filed: November 3, 2016
    Publication date: March 9, 2017
    Applicant: G1 THERAPEUTICS, INC.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • LACTAM KINASE INHIBITORS
    Publication number: 20170057972
    Abstract: Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventor: Francis Xavier Tavares
  • CDK Inhibitors
    Publication number: 20170057971
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Applicant: G1 THERAPEUTICS, INC.
    Inventors: Francis X. Tavares, Jay C. Strum
  • TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY
    Publication number: 20170037051
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Application
    Filed: October 7, 2016
    Publication date: February 9, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • CDK inhibitors
    Patent number: 9499564
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: November 22, 2016
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum